Pub Date : 2018-12-05DOI: 10.30683/1927-7229.2019.08.10
A. Chairmadurai
: Bystander toxicity and tissue fibrosis are the major complications with conventional radiation therapy for cancer patients. In this context, we here propose RapidArc - Stereotactic Body Radiation Therapy (Ra-SBRT) as a noninvasive and immune adjuvant approach for the successful eradication of advance stage NSCLC. Ra-SBRT is highly focused and capable of destroying tumors with high grade metastatic lesions and spared normal tissues. Follow up of stage 4 th NSCLC patient revealed that Ra-SBRT is potentially immunogenic which was evident by increased number of iNOS+ Tumor Associated macrophages (M1-TAM), Siglac-8+ eosinophils, basophils and subsequent prolongation of disease free survival of 4 th stage NSCLC patients by 3 years. This study demonstrated M1 retuning potential of Ra-SBRT which is a pre-requisite of effective management of inoperable and highly metastatic tumors of lung with least or no bystander impact.
{"title":"Ra-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients","authors":"A. Chairmadurai","doi":"10.30683/1927-7229.2019.08.10","DOIUrl":"https://doi.org/10.30683/1927-7229.2019.08.10","url":null,"abstract":": Bystander toxicity and tissue fibrosis are the major complications with conventional radiation therapy for cancer patients. In this context, we here propose RapidArc - Stereotactic Body Radiation Therapy (Ra-SBRT) as a noninvasive and immune adjuvant approach for the successful eradication of advance stage NSCLC. Ra-SBRT is highly focused and capable of destroying tumors with high grade metastatic lesions and spared normal tissues. Follow up of stage 4 th NSCLC patient revealed that Ra-SBRT is potentially immunogenic which was evident by increased number of iNOS+ Tumor Associated macrophages (M1-TAM), Siglac-8+ eosinophils, basophils and subsequent prolongation of disease free survival of 4 th stage NSCLC patients by 3 years. This study demonstrated M1 retuning potential of Ra-SBRT which is a pre-requisite of effective management of inoperable and highly metastatic tumors of lung with least or no bystander impact.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78218845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-05DOI: 10.30683/1927-7229.2019.08.02
Hashmath Khanum
: Purpose : To evaluate the efficiency of glutamine in the prevention & treatment of mucositis in head and neck cancer patients undergoing chemoradiation. Material and Methods : Forty patients of histologically proven head and neck carcinomas undergoing chemoradiation with Conventional Radiation on telecobalt and concurrent Cisplatin were randomised into 2 groups. The study group received oral glutamine solution 2 hours prior to undergoing radiotherapy on all days of treatment. The severity and duration of mucositis were recorded once every week using WHO and RTOG grading system for all patients undergoing treatment. Results : Glutamine lead to a delay in the onset of mucositis. The overall incidence of grade ≥ 3 mucositis was significantly low in glutamine arm (22% vs 55%, p= 0.006). On weekly assessments, the incidence of grade ≥ 3 mucositis in study arm compared to the control was 0 vs 30%, p=0.02 at 4 weeks, 15.8 vs 45%, p= 0.038 at 5 weeks and 22 vs 70%, p=0.001 at 6 weeks. However, there was no statistically significant difference in the incidence of grade 1 and 2 mucositis in both arms. Conclusion : Use of oral glutamine reduces the incidence and duration of oral mucositis and hence helpful in the prevention and treatment of oral mucositis with good compliance and further result in good locoregional control of the disease.
目的:评价谷氨酰胺在头颈部肿瘤放化疗患者黏膜炎防治中的作用。材料与方法:将40例经组织学证实的头颈部癌患者随机分为两组，分别接受常规放射治疗和顺铂治疗。研究组在放疗前2小时口服谷氨酰胺溶液。使用WHO和RTOG分级系统对所有接受治疗的患者每周记录一次黏膜炎的严重程度和持续时间。结果:谷氨酰胺可延缓黏膜炎的发病。谷氨酰胺组≥3级粘膜炎的总发生率明显较低(22% vs 55%， p= 0.006)。在每周评估中，与对照组相比，研究组≥3级粘膜炎的发生率为0 vs 30%，第4周时p=0.02，第5周时为15.8 vs 45%，第6周时为22 vs 70%， p=0.001。然而，两组1级和2级粘膜炎的发生率无统计学差异。结论:口服谷氨酰胺可降低口腔黏膜炎的发病率和病程，有助于预防和治疗口腔黏膜炎，依从性好，局部控制效果好。
{"title":"Role of Oral Glutamine in Prevention and Treatment of Oral Mucositis in Head and Neck Cancer Patients Receiving Chemoradiation","authors":"Hashmath Khanum","doi":"10.30683/1927-7229.2019.08.02","DOIUrl":"https://doi.org/10.30683/1927-7229.2019.08.02","url":null,"abstract":": Purpose : To evaluate the efficiency of glutamine in the prevention & treatment of mucositis in head and neck cancer patients undergoing chemoradiation. Material and Methods : Forty patients of histologically proven head and neck carcinomas undergoing chemoradiation with Conventional Radiation on telecobalt and concurrent Cisplatin were randomised into 2 groups. The study group received oral glutamine solution 2 hours prior to undergoing radiotherapy on all days of treatment. The severity and duration of mucositis were recorded once every week using WHO and RTOG grading system for all patients undergoing treatment. Results : Glutamine lead to a delay in the onset of mucositis. The overall incidence of grade ≥ 3 mucositis was significantly low in glutamine arm (22% vs 55%, p= 0.006). On weekly assessments, the incidence of grade ≥ 3 mucositis in study arm compared to the control was 0 vs 30%, p=0.02 at 4 weeks, 15.8 vs 45%, p= 0.038 at 5 weeks and 22 vs 70%, p=0.001 at 6 weeks. However, there was no statistically significant difference in the incidence of grade 1 and 2 mucositis in both arms. Conclusion : Use of oral glutamine reduces the incidence and duration of oral mucositis and hence helpful in the prevention and treatment of oral mucositis with good compliance and further result in good locoregional control of the disease.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72978863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-05DOI: 10.30683/1927-7229.2019.08.03
Cardile Venera
: Prostate cancer is one of the most common forms of cancer in men and continues to be a problem in the developed world. The treatment approaches for androgen-independent prostate cancer are unsatisfactory and the survival of those patients remains poor. Thus, there is a strong demand to develop novel therapeutic agents to treat and prevent this advanced malignancy. The present study evaluated the effect of boldine (2,9-dihydroxy-1,10-dimethoxy-aporphine), an aporphine alkaloid occurs abundantly in the leaves of Boldo ( Peumus boldus Molina), on growth and cell death of DU-145 androgen-independent prostate cancer cell line. The cell viability was measured by MTT test and LDH release was used to quantify necrosis cell death. Genomic DNA, caspase-3 activity, expression of cleaved caspase-9, Hsp70, Bcl-2 and Bax proteins were analyzed in order to study the apoptotic process. The results showed that boldine was able to reduce cell viability in the range of 60-240 µ M concentrations, and suggest this aporphine alkaloid induces cell death by intrinsic apoptotic pathway that probably involves the down-regulation of heat shock protein 70 (Hsp70). In fact, an increase of caspase-3 enzyme activity and Bax protein expression, in conjunction with the more pronounced decrease in Bcl-2 occurred in DU-145 cells treated with boldine at 60-120 µ M concentrations. In addition, caspase-9 was shown to be observably activated. Moreover, boldine such as quercetin, a well-known Hsp70 protein inhibitor, induced a reduction of Hsp70 expression. The hypothesis of apoptosis induction in our experimental conditions was reinforced by a high DNA fragmentation at 60-120 µ M concentrations, not correlated to LDH release. The present findings, starting point for further investigation, suggest that boldine structure might be used to design novel derivatives for the developing of potential new drugs for advanced prostate cancer therapy.
{"title":"Boldine Activates Intrinsic Apoptotic Pathway in DU-145 Androgen-Independent Prostate Cancer Cell Line","authors":"Cardile Venera","doi":"10.30683/1927-7229.2019.08.03","DOIUrl":"https://doi.org/10.30683/1927-7229.2019.08.03","url":null,"abstract":": Prostate cancer is one of the most common forms of cancer in men and continues to be a problem in the developed world. The treatment approaches for androgen-independent prostate cancer are unsatisfactory and the survival of those patients remains poor. Thus, there is a strong demand to develop novel therapeutic agents to treat and prevent this advanced malignancy. The present study evaluated the effect of boldine (2,9-dihydroxy-1,10-dimethoxy-aporphine), an aporphine alkaloid occurs abundantly in the leaves of Boldo ( Peumus boldus Molina), on growth and cell death of DU-145 androgen-independent prostate cancer cell line. The cell viability was measured by MTT test and LDH release was used to quantify necrosis cell death. Genomic DNA, caspase-3 activity, expression of cleaved caspase-9, Hsp70, Bcl-2 and Bax proteins were analyzed in order to study the apoptotic process. The results showed that boldine was able to reduce cell viability in the range of 60-240 µ M concentrations, and suggest this aporphine alkaloid induces cell death by intrinsic apoptotic pathway that probably involves the down-regulation of heat shock protein 70 (Hsp70). In fact, an increase of caspase-3 enzyme activity and Bax protein expression, in conjunction with the more pronounced decrease in Bcl-2 occurred in DU-145 cells treated with boldine at 60-120 µ M concentrations. In addition, caspase-9 was shown to be observably activated. Moreover, boldine such as quercetin, a well-known Hsp70 protein inhibitor, induced a reduction of Hsp70 expression. The hypothesis of apoptosis induction in our experimental conditions was reinforced by a high DNA fragmentation at 60-120 µ M concentrations, not correlated to LDH release. The present findings, starting point for further investigation, suggest that boldine structure might be used to design novel derivatives for the developing of potential new drugs for advanced prostate cancer therapy.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"38 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89654593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-05DOI: 10.30683/1927-7229.2019.08.08
Mahdi Fatemizadeh
: The main purpose of this study was to investigate the impact of acceptance and commitment group therapy on pain tolerance and state-trait anxiety in patients with gastrointestinal cancer. This quasi-experimental study was performed with pretest, posttest and control group. There were 24 participants in the study, 12 of them in the control group and other 12 in the experimental group. The experimental group received eight sessions of acceptance and commitment based therapy and the control group received no psychotherapy. The instruments used in this study were short-form McGill Pain questionnaire-2 and state-trait anxiety questionnaire. Results showed an increase in pain tolerance and decrease in anxiety in patients in the experimental group.
{"title":"The Role of Acceptance and Commitment-based Group Therapy on Pain Tolerance and State-trait Anxiety in Gastrointestinal Cancer Patients","authors":"Mahdi Fatemizadeh","doi":"10.30683/1927-7229.2019.08.08","DOIUrl":"https://doi.org/10.30683/1927-7229.2019.08.08","url":null,"abstract":": The main purpose of this study was to investigate the impact of acceptance and commitment group therapy on pain tolerance and state-trait anxiety in patients with gastrointestinal cancer. This quasi-experimental study was performed with pretest, posttest and control group. There were 24 participants in the study, 12 of them in the control group and other 12 in the experimental group. The experimental group received eight sessions of acceptance and commitment based therapy and the control group received no psychotherapy. The instruments used in this study were short-form McGill Pain questionnaire-2 and state-trait anxiety questionnaire. Results showed an increase in pain tolerance and decrease in anxiety in patients in the experimental group.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"255 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83495928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-05DOI: 10.30683/1927-7229.2019.08.09
K. Gupta
: Glypicans (GPCs) are a family of proteoglycans that are bound to the cell surface by a glycosyl- phosphatidylinositol anchor. Six glypicans have been found in the mammalian genome (GPC1 to GPC6). Glypicans can be released from the cell surface by a lipase called Notum, and most of them are subjected to endoproteolytic cleavage by furin-like convertases. In vivo evidence published so far indicates that the main function of membrane-attached glypicans is to regulate the signaling of Wnts, Hedgehogs, fibroblast growth factors and bone morphogenetic proteins (BMPs). Surprisingly, the regulatory activity of glypicans in the Wnt, Hedgehog and BMP signaling pathways is only partially dependent on the heparan sulfate chains. It is obvious that our knowledge of glypican functions is still very limited despite the recent advances. A better understanding of these functions will make a significant contribution to the study of signaling pathways that play a very important role in developmental morphogenesis and several human diseases, including cancer.
{"title":"Glypicans - A Brief Review","authors":"K. Gupta","doi":"10.30683/1927-7229.2019.08.09","DOIUrl":"https://doi.org/10.30683/1927-7229.2019.08.09","url":null,"abstract":": Glypicans (GPCs) are a family of proteoglycans that are bound to the cell surface by a glycosyl- phosphatidylinositol anchor. Six glypicans have been found in the mammalian genome (GPC1 to GPC6). Glypicans can be released from the cell surface by a lipase called Notum, and most of them are subjected to endoproteolytic cleavage by furin-like convertases. In vivo evidence published so far indicates that the main function of membrane-attached glypicans is to regulate the signaling of Wnts, Hedgehogs, fibroblast growth factors and bone morphogenetic proteins (BMPs). Surprisingly, the regulatory activity of glypicans in the Wnt, Hedgehog and BMP signaling pathways is only partially dependent on the heparan sulfate chains. It is obvious that our knowledge of glypican functions is still very limited despite the recent advances. A better understanding of these functions will make a significant contribution to the study of signaling pathways that play a very important role in developmental morphogenesis and several human diseases, including cancer.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87465009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-05DOI: 10.30683/1927-7229.2019.08.04
Autumn J. Smith
: The first clinical trials to investigate the efficacy of immunotherapy in cancer were problematic because of issues related to product availability, cost, and purity. Moreover, these factors could have contributed to the modest efficacy of these agents. The ability to clone specific genes coupled with the development of recombinant DNA technology removed some major barriers such that only 20 years later, approval of the first engineered monoclonal antibody (mAb) for clinical use occurred with practice-changing implications. Subsequent to rituximab, more than 30 additional mAbs have indications for a number of hematologic malignancies and solid tumors. Indeed, the application of adaptive immunity is now an integral component of therapy for many cancers. This paper delves into the complex science of immunology by investigating how the term evolution is applicable to tumorigenesis, the adaptive immune response, and cancer therapy.
{"title":"Evolution of Cancer, Adaptive Immunity, and Immunotherapy","authors":"Autumn J. Smith","doi":"10.30683/1927-7229.2019.08.04","DOIUrl":"https://doi.org/10.30683/1927-7229.2019.08.04","url":null,"abstract":": The first clinical trials to investigate the efficacy of immunotherapy in cancer were problematic because of issues related to product availability, cost, and purity. Moreover, these factors could have contributed to the modest efficacy of these agents. The ability to clone specific genes coupled with the development of recombinant DNA technology removed some major barriers such that only 20 years later, approval of the first engineered monoclonal antibody (mAb) for clinical use occurred with practice-changing implications. Subsequent to rituximab, more than 30 additional mAbs have indications for a number of hematologic malignancies and solid tumors. Indeed, the application of adaptive immunity is now an integral component of therapy for many cancers. This paper delves into the complex science of immunology by investigating how the term evolution is applicable to tumorigenesis, the adaptive immune response, and cancer therapy.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79533799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-05DOI: 10.30683/1927-7229.2019.08.05
K. Gupta
: The aim of this study was to investigate the presence of mast cells in a series of odontogenic tumors. Forty- five cases of odontogenic tumors were investigated using 1% toluidine blue for mast cells, and differences between groups were statistically evaluated. Mast cells were present in 96% of odontogenic tumors. Mast cells are probably one of the major components of the Stromal scaffold in odontogenic tumors.
{"title":"Quantitative Analysis of Mast Cells in Benign Odontogenic Tumors","authors":"K. Gupta","doi":"10.30683/1927-7229.2019.08.05","DOIUrl":"https://doi.org/10.30683/1927-7229.2019.08.05","url":null,"abstract":": The aim of this study was to investigate the presence of mast cells in a series of odontogenic tumors. Forty- five cases of odontogenic tumors were investigated using 1% toluidine blue for mast cells, and differences between groups were statistically evaluated. Mast cells were present in 96% of odontogenic tumors. Mast cells are probably one of the major components of the Stromal scaffold in odontogenic tumors.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85952020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-07-26DOI: 10.6000/1927-7229.2018.07.03.1
M. Mahrous, Tasabeeh Mohamed, Ghassan Al Sisi, A. Hujaily, Samira AlSumani
Background : Primary squamous cell carcinoma of the breast (PSCCB) is a very rare malignancy of the breast. Pure squamous cell carcinoma of the breast can originate from skin adnexa, the nipple or the epithelium of deep-seated epidermoid cyst or squamous metaplasia on chronic inflammation background. Case Report : Our case is a 49-year-old female patient who presented with a highly suspicious lump in her left breast. Bilateral mammography and core biopsy were carried out. The core biopsy was revealed atypical cells and review inconclusive. Incisional biopsy was done and revealed squamous cell carcinoma of the breast (SCCB). Her metastatic work up at presentation was unremarkable. Left-side modified radical mastectomy was carried out. TNM staging was Stage IIa pT2N0M0 GIII, Estrogen receptors (ER) and Progesterone receptors were negative and HER2/Neu was negative as well (Triple negative). Pt had adjuvant chemotherapy and radiotherapy. Eight months later, she developed multiple brain metastasis as solitary site of metastasis, then after four months she developed hepatic and pulmonary deposits. Pt survived only 25 months since disease diagnosis. We report this case with relatively younger age to confirm that primary squamous cell carcinoma of the breast has special aggressive entity and this conjugant with few series. The treatment of primary SqCC of the breast does not differ from other common histological types of breast cancer so far. Conclusions : The prognosis of this disease is highly uncertain and the treatment options are unclear and controversial. There is inadequate literature and treatment guidelines. To our knowledge it is the first case to be reported from arab region with aggressive behavior and short survival period.
{"title":"Primary Squamous Cell Carcinoma of the Breast is a Rare and Special Entity. A Case Report from Arab Region with Aggressive Behavior and follow up 25 Months","authors":"M. Mahrous, Tasabeeh Mohamed, Ghassan Al Sisi, A. Hujaily, Samira AlSumani","doi":"10.6000/1927-7229.2018.07.03.1","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.03.1","url":null,"abstract":"Background : Primary squamous cell carcinoma of the breast (PSCCB) is a very rare malignancy of the breast. Pure squamous cell carcinoma of the breast can originate from skin adnexa, the nipple or the epithelium of deep-seated epidermoid cyst or squamous metaplasia on chronic inflammation background. Case Report : Our case is a 49-year-old female patient who presented with a highly suspicious lump in her left breast. Bilateral mammography and core biopsy were carried out. The core biopsy was revealed atypical cells and review inconclusive. Incisional biopsy was done and revealed squamous cell carcinoma of the breast (SCCB). Her metastatic work up at presentation was unremarkable. Left-side modified radical mastectomy was carried out. TNM staging was Stage IIa pT2N0M0 GIII, Estrogen receptors (ER) and Progesterone receptors were negative and HER2/Neu was negative as well (Triple negative). Pt had adjuvant chemotherapy and radiotherapy. Eight months later, she developed multiple brain metastasis as solitary site of metastasis, then after four months she developed hepatic and pulmonary deposits. Pt survived only 25 months since disease diagnosis. We report this case with relatively younger age to confirm that primary squamous cell carcinoma of the breast has special aggressive entity and this conjugant with few series. The treatment of primary SqCC of the breast does not differ from other common histological types of breast cancer so far. Conclusions : The prognosis of this disease is highly uncertain and the treatment options are unclear and controversial. There is inadequate literature and treatment guidelines. To our knowledge it is the first case to be reported from arab region with aggressive behavior and short survival period.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"33 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87687592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-07-26DOI: 10.6000/1927-7229.2018.07.03.4
L. Cole
Tumor marker studies were conducted measuring 2,277 malignancies using a cut-off of 3 fmol/ml. As found 110 of 110 trophoblastic malignancies or 100% were positive for s-core fragment an hCG serum degradation product. Just 949 of 2167 (44%) of non-trophoblastic or other cancers were positive using this 3 fmol/ml cut-off. When the cut-off of the assay was lowered to 0.1 fmol/ml, or lowered by 30-fold 100% of non-trophoblastic or other cancers were detected, or all cancers were detected. What do cancers secrete. Cancer were tested with three immunoassays, Immulite total hCG, B152 hyperglycosylated hCG and FBT11 free s-subunit, serum of 34 trophoblastic cancers and 32 non-trophoblastic cancers were tested. A total of 34 of 34 trophoblastic cancer produced primarily hyperglycosylated hCG (B152 hyperglycosylated assay 96%±12% of Immulite), and 32 of 32 non-trophoblastic cancers produced primarily hyperglycosylated hCG free s-subunit (B152 hyperglycosylated assay 102%±6.2% of Immulite, FBT11 free s-subunit assay 128%±10% of Immulite). Seven independent laboratories each showed with a wide mixture of cancers (patient tissue and cancer cell lines) that s-subunit promoted malignancy (cell growth, cell invasion and blockage of apoptosis) in cancer cells. I then showed that hyperglycosylated hCG and its s-subunit promoted malignancy in 10 different cancer cell lines. I then tied my data and the seven independent laboratory data together and concluded that hyperglycosylated hCG and its s-subunit drove malignancy in all or most cancers.
{"title":"Hyperglycosylated hCG and Its Free ß-Subunit Drives Malignancy","authors":"L. Cole","doi":"10.6000/1927-7229.2018.07.03.4","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.03.4","url":null,"abstract":"Tumor marker studies were conducted measuring 2,277 malignancies using a cut-off of 3 fmol/ml. As found 110 of 110 trophoblastic malignancies or 100% were positive for s-core fragment an hCG serum degradation product. Just 949 of 2167 (44%) of non-trophoblastic or other cancers were positive using this 3 fmol/ml cut-off. When the cut-off of the assay was lowered to 0.1 fmol/ml, or lowered by 30-fold 100% of non-trophoblastic or other cancers were detected, or all cancers were detected. What do cancers secrete. Cancer were tested with three immunoassays, Immulite total hCG, B152 hyperglycosylated hCG and FBT11 free s-subunit, serum of 34 trophoblastic cancers and 32 non-trophoblastic cancers were tested. A total of 34 of 34 trophoblastic cancer produced primarily hyperglycosylated hCG (B152 hyperglycosylated assay 96%±12% of Immulite), and 32 of 32 non-trophoblastic cancers produced primarily hyperglycosylated hCG free s-subunit (B152 hyperglycosylated assay 102%±6.2% of Immulite, FBT11 free s-subunit assay 128%±10% of Immulite). Seven independent laboratories each showed with a wide mixture of cancers (patient tissue and cancer cell lines) that s-subunit promoted malignancy (cell growth, cell invasion and blockage of apoptosis) in cancer cells. I then showed that hyperglycosylated hCG and its s-subunit promoted malignancy in 10 different cancer cell lines. I then tied my data and the seven independent laboratory data together and concluded that hyperglycosylated hCG and its s-subunit drove malignancy in all or most cancers.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86464144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-07-26DOI: 10.6000/1927-7229.2018.07.03.2
Herve Kada Pabame, R. Simo, A. H. N. Kamdje, Louis Deweerdt, Guillaume Gayma, Franklin Danki Sillong
Introduction : The number of prostate cancer detected late because of the lack of means of investigation allowing a proximity screening, the poverty which characterize north are the two main elements which led us to lead this study which had for objective to shown the value of using rapid PSA screening tests. Method : We conducted a cross-sectional analytical study in the city of Ngaoundere and Garoua for a period of 5 months. Results : A total of 220 PSA level assays were performed over the 5-month period of our study with variations between the two selected centers. Of 30 samples used to study the sensitivity of rapid PSA screening tests, 22 were positive and 8 negative. The concordance rate for the positive values of the rapid test strip test versus the assay was 100%. The concordance of negative values was 87.5%. In addition, in a sample of 41 patients, PSA tests were performed in 30 patients, or 73.17%, and diagnosed prostate cancer in 69.23% of diagnosed cancer cases. Conclusion : Rapid PSA screening tests are good tools for diagnosing prostate cancer when combined with other tools such as digital rectal examination and ultrasound.
{"title":"Interests in the use of Rapid Prostate Antigen Screening Test in the North-Cameroon","authors":"Herve Kada Pabame, R. Simo, A. H. N. Kamdje, Louis Deweerdt, Guillaume Gayma, Franklin Danki Sillong","doi":"10.6000/1927-7229.2018.07.03.2","DOIUrl":"https://doi.org/10.6000/1927-7229.2018.07.03.2","url":null,"abstract":"Introduction : The number of prostate cancer detected late because of the lack of means of investigation allowing a proximity screening, the poverty which characterize north are the two main elements which led us to lead this study which had for objective to shown the value of using rapid PSA screening tests. Method : We conducted a cross-sectional analytical study in the city of Ngaoundere and Garoua for a period of 5 months. Results : A total of 220 PSA level assays were performed over the 5-month period of our study with variations between the two selected centers. Of 30 samples used to study the sensitivity of rapid PSA screening tests, 22 were positive and 8 negative. The concordance rate for the positive values of the rapid test strip test versus the assay was 100%. The concordance of negative values was 87.5%. In addition, in a sample of 41 patients, PSA tests were performed in 30 patients, or 73.17%, and diagnosed prostate cancer in 69.23% of diagnosed cancer cases. Conclusion : Rapid PSA screening tests are good tools for diagnosing prostate cancer when combined with other tools such as digital rectal examination and ultrasound.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84085620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：